AGFG1

Across TCGA pan-cancer cohorts, AGFG1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGFG1 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGFG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGFG1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where AGFG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.338	0.778	.014	19	view →
GBM	OS	Tertile	All	0.361	0.621	.009	7	view →
LSCC	DFS	Quartile	II,III,IV	0.504	0.879	.012	7	view →
PDAC	OS	Median	III,IV	0.603	0.266	.024	5	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	3	view →
HNSC	DFS	Quartile	All	0.895	1.000	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGFG1–LUAD (OS)

Open the LUAD breakdown →